A case of a renal transplant recipient with colchicine-induced myopathy is presented. He was on colchicine therapy for 10 months. He was hospitalized for investigation of fatigue, severe myalgia in the lower extremities and elevated serum aminotransferase levels. His viral markers and other factors that may cause myalgia and that may increase the serum aminotransferase levels were either normal or negative. Creatine phosphokinase (CK) levels were normal. Electrophysiological findings indicated myopathy and muscle biopsy was consistent with vacuolar myopathy. After withdrawal of colchicine, the symptoms disappeared gradually and serum aminotransferase levels were normalized. We suggest that colchicine myopathy should be taken into account in patients who have been on colchicine therapy and had unexplained myalgia as well as elevated aminotransferase levels even with normal CK levels.

Keywords:
Colchicine, Myopathy, Renal transplantation
1.
Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M: Colchicine myopathy and neuropathy. N Engl J Med 1987;316:1562–1568.
2.
Ducloux D, Schuller V, Bresson-Vautrin C, Chalopin JM: Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant 1997;12:2389–2392.
3.
Wallace SL, Singer JZ, Duncan GJ, Wipley FM, Kuncl RV: Renal function predicts colchicine toxicity: Guidelines for the use of colchicine in gout. J Rheumatol 1991;18:264–269.
4.
Dawson TM, Starkebaum G: Colchicine induced rhabdomyolysis. J Rheumatol 1997;24:2045–2046.
5.
Bohan A, Peters JB, Bowman RL, Pearson CM: A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1997;255–286.
6.
Kagen LJ, Aram S: Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 1987;30:213–217.
7.
Rumph KW, Henning HV: Is myopathy in renal transplant patients induced by cyclosporine or colchicine? Lancet 1990;335:800–801.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.